AZ loses round in Lucentis patent fight

An English judge has dealt a blow to AstraZeneca by overruling the patent rights of MedImmune, its subsidiary, to a screening technique used in drugs like Roche's blockbuster eye treatment Lucentis. The two companies are also litigating over the patent rights in other countries including France, Germany, the Netherlands and Switzerland. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.